SignatureFD’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | – | Sell |
-1,384
| Closed | -$43.5K | – | 3578 |
|
|
2026
Q2 | $43.5K | Buy |
1,384
+895
| +183% | +$26.4K | ﹤0.01% | 1953 |
|
|
2026
Q1 | $12.1K | Buy |
489
+404
| +475% | +$9.6K | ﹤0.01% | 2422 |
|
|
2025
Q4 | $1.98K | Hold |
85
| – | – | ﹤0.01% | 2973 |
|
|
2025
Q3 | $1.68K | Sell |
85
-9
| -10% | -$185 | ﹤0.01% | 2995 |
|
|
2025
Q2 | $2.04K | Sell |
94
-72
| -43% | -$1.7K | ﹤0.01% | 2859 |
|
|
2025
Q1 | $4.03K | Buy |
166
+72
| +77% | +$1.62K | ﹤0.01% | 2680 |
|
|
2024
Q4 | $1.96K | Sell |
94
-11
| -10% | -$236 | ﹤0.01% | 2877 |
|
|
2024
Q3 | $2.09K | Hold |
105
| – | – | ﹤0.01% | 2825 |
|
|
2024
Q2 | $1.63K | Hold |
105
| – | – | ﹤0.01% | 2812 |
|
|
2024
Q1 | $1.67K | Hold |
105
| – | – | ﹤0.01% | 2849 |
|
|
2023
Q4 | $1.76K | Hold |
105
| – | – | ﹤0.01% | 2791 |
|
|
2023
Q3 | $1.23K | Hold |
105
| – | – | ﹤0.01% | 2893 |
|
|
2023
Q2 | $1.41K | Hold |
105
| – | – | ﹤0.01% | 2895 |
|
|
2023
Q1 | $1.74K | Sell |
105
-37
| -26% | -$610 | ﹤0.01% | 2843 |
|
|
2022
Q4 | $2.64K | Buy |
142
+37
| +35% | +$570 | ﹤0.01% | 2715 |
|
|
2022
Q3 | $1K | Buy |
105
+71
| +209% | +$841 | ﹤0.01% | 2932 |
|
|
2022
Q2 | $0 | Buy |
+34
| New | +$249 | ﹤0.01% | 3146 |
|
|
2014
Q3 | – | Sell |
-3,000
| Closed | -$8K | – | 738 |
|
|
2014
Q2 | $8K | Buy |
+3,000
| New | +$6.41K | ﹤0.01% | 488 |
|
Other funds holding CPRX
SignatureFD's CPRX Position: Q3 2026 in Review
SignatureFD sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 1,384 shares — an estimated $43.5K sold.
SignatureFD first reported a position in CPRX in Q2 2014 and held it in 18 quarters. The position peaked at $43.5K in Q2 2026. 1 fund tracked by Wall St. Rank holds CPRX as of Q3 2026.
- SignatureFD reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
- SignatureFD sold 1,384 Catalyst Pharmaceutical shares in Q3 2026, an estimated $43.5K.
- SignatureFD first reported a position in Catalyst Pharmaceutical in Q2 2014 and held it in 18 quarters.
- SignatureFD's Catalyst Pharmaceutical position peaked at $43.5K in Q2 2026.
- 1 fund tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.
Based on SignatureFD's 13F filing for Q3 2026, filed 23 Oct 2026.